universe pharmaceuticals inc - UPC

UPC

Close Chg Chg %
3.98 0.00 0.00%

Closed Market

3.98

0.00 (0.00%)

Volume: 7.49K

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Company Overview: universe pharmaceuticals inc - UPC

UPC Key Data

Open

$4.05

Day Range

3.96 - 4.10

52 Week Range

2.51 - 13.95

Market Cap

$2.47M

Shares Outstanding

563.34K

Public Float

552.61K

Beta

1.52

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

N/A

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

24.88K

 

UPC Performance

1 Week
 
-9.95%
 
1 Month
 
-7.66%
 
3 Months
 
5.57%
 
1 Year
 
-45.92%
 
5 Years
 
N/A
 

UPC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About universe pharmaceuticals inc - UPC

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

UPC At a Glance

Universe Pharmaceuticals, Inc.
265 Jingjiu Avenue
Ji'an, Jiangxi 343100
Phone 86-796-8403309 Revenue 17.86M
Industry Pharmaceuticals: Major Net Income -3,672,055.00
Sector Health Technology Employees 216
Fiscal Year-end 09 / 2026
View SEC Filings

UPC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.107
Price to Book Ratio 0.042
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 9.348
Enterprise Value to Sales -1.255
Total Debt to Enterprise Value -0.413

UPC Efficiency

Revenue/Employee 82,679.315
Income Per Employee -17,000.255
Receivables Turnover 1.354
Total Asset Turnover 0.26

UPC Liquidity

Current Ratio 4.069
Quick Ratio 3.713
Cash Ratio 2.55

UPC Profitability

Gross Margin 32.925
Operating Margin -16.328
Pretax Margin -20.926
Net Margin -20.562
Return on Assets -5.351
Return on Equity -7.226
Return on Total Capital -5.616
Return on Invested Capital -7.077

UPC Capital Structure

Total Debt to Total Equity 16.492
Total Debt to Total Capital 14.157
Total Debt to Total Assets 13.357
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Universe Pharmaceuticals Inc - UPC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
40.14M 32.31M 23.02M 17.86M
Sales Growth
-16.34% -19.52% -28.74% -22.44%
Cost of Goods Sold (COGS) incl D&A
18.46M 22.23M 17.20M 11.98M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
533.95K 508.79K 485.73K 517.43K
Depreciation
528.92K 503.69K 474.03K 474.18K
Amortization of Intangibles
5.03K 5.10K 11.70K 43.25K
COGS Growth
-19.21% +20.44% -22.63% -30.36%
Gross Income
21.69M 10.08M 5.82M 5.88M
Gross Income Growth
-13.73% -53.53% -42.21% +0.97%
Gross Profit Margin
+54.02% +31.19% +25.29% +32.93%
2022 2023 2024 2025 5-year trend
SG&A Expense
28.92M 13.43M 13.60M 8.80M
Research & Development
7.62M 4.82M 2.99M 496.95K
Other SG&A
21.30M 8.61M 10.60M 8.30M
SGA Growth
+155.44% -53.57% +1.28% -35.31%
Other Operating Expense
- 205.58K 179.19K 246.24K
Unusual Expense
- - - 481.11K
-
EBIT after Unusual Expense
(7.44M) (3.53M) (8.02M) (3.40M)
Non Operating Income/Expense
(421.54K) (197.08K) 145.48K (108.04K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
162.40K 156.79K 278.17K 232.04K
Interest Expense Growth
+59.84% -3.46% +77.42% -16.58%
Gross Interest Expense
162.40K 156.79K 278.17K 232.04K
Interest Capitalized
- - - -
-
Pretax Income
(8.02M) (3.88M) (8.15M) (3.74M)
Pretax Income Growth
-158.78% +51.63% -110.08% +54.16%
Pretax Margin
-19.99% -12.01% -35.41% -20.93%
Income Tax
- 752.42K 2.31M 606.70K
Income Tax - Current - Domestic
- - 1.36M 685.94K
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (605.28K) 1.63M 606.70K
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(8.74M) (6.16M) (8.73M) (3.67M)
Minority Interest Expense
- - - -
-
Net Income
(8.74M) (6.16M) (8.73M) (3.67M)
Net Income Growth
-177.18% +29.46% -41.61% +57.92%
Net Margin Growth
-21.76% -19.08% -37.90% -20.56%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(8.74M) (6.16M) (8.73M) (3.67M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(8.74M) (6.16M) (8.73M) (3.67M)
EPS (Basic)
-1446.0479 -1020.0899 -376176.6172 -8.055
EPS (Basic) Growth
-177.18% +29.46% -36,776.81% +100.00%
Basic Shares Outstanding
6.04K 6.04K 23.200001160000003 455.87K
EPS (Diluted)
-1446.0479 -1020.0899 -376176.6172 -8.055
EPS (Diluted) Growth
-177.18% +29.46% -36,776.81% +100.00%
Diluted Shares Outstanding
6.04K 6.04K 23.200001160000003 455.87K
EBITDA
(6.90M) (3.02M) (7.53M) (2.40M)
EBITDA Growth
-149.19% +56.29% -149.64% +68.16%
EBITDA Margin
-17.20% -9.34% -32.72% -13.43%

Universe Pharmaceuticals Inc in the News